Skip to main content

Market Overview

Recap: PRA Health Sciences Q4 Earnings



Shares of PRA Health Sciences (NASDAQ:PRAH) rose 20.6% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share rose 0.65% year over year to $1.55, which beat the estimate of $1.47.

Revenue of $873,458,000 rose by 9.15% year over year, which beat the estimate of $829,020,000.


PRA Health Sciences hasn't issued any earnings guidance for the time being.

PRA Health Sciences hasn't issued any revenue guidance for the time being.


Company's 52-week high was at $137.88

Company's 52-week low was at $58.67

Price action over last quarter: Up 35.55%

Company Overview

PRA Health Sciences is a global contract research organization that provides drug development and clinical trial services to pharmaceutical and biotechnology firms. Its services run from early- to late-stage clinical trial outsourcing with varying levels of support, including one-off specialized staffing services to strategic partnerships where PRA handles nearly all aspects of the trial. In 2017, PRA acquired Symphony Health, a healthcare data and analytics provider.


Related Articles (PRAH)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at